Is JNJ's Rally Running Out of Steam?

Johnson & Johnson (JNJ) has been on a remarkable run, with its stock price increasing by 56% over the past year. This outperformance has left investors wondering whether there's still room to invest in the company or if the price has already reflected all the good news.

The company's strong momentum is backed by its elite business quality, with an operating margin of 27% over the last year, significantly higher than the S&P 500 median of 18.5%. The Innovative Medicine business is driving growth, with key drugs such as TREMFYA and DARZALEX posting remarkable sales increases.

However, not everything is rosy. The MedTech division is showing signs of strain, with a 2% sales decline in the Abiomed heart recovery business attributed to 'pressures on U.S. procedures'. This slowdown poses a significant risk to the stock's continued growth.